Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 23;138(25):2670–2685. doi: 10.1182/blood.2020009530

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by The American Society of Hematology

This article is made available via the PMC Open Access Subset for unrestricted reuse and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. — EFS and OS from first line-treatment, stratified according to the TP53 mutation load. (A) EFS of the whole cohort. (B) EFS in patients with unmutated IGHV. (C) OS of the whole cohort. (D) OS in patients stratified according to a targeted treatment. Dashed line, patients received targeted treatment with either BcR inhibitors (ibrutinib, idelalisib, or acalabrutinib) or bcl2 inhibitor (venetoclax) in later stages of the disease. Patients undergoing allogeneic hemapoietic stem cell transplant were excluded (n = 14). (E) OS in a cohort with unmutated IGHV, with patients switched to targeted agents or undergoing allogeneic hemapoietic stem cell transplant excluded. All analyses were also performed for time to second treatment and for FCR-treated patients only, and very similar results were obtained (data not shown).